Roman Butler Fullerton & Co. Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Roman Butler Fullerton & Co. acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 4th quarter, Holdings Channel.com reports. The firm acquired 8,837 shares of the company’s stock, valued at approximately $1,256,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Livforsakringsbolaget Skandia Omsesidigt lifted its position in shares of Neurocrine Biosciences by 57.9% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 3,000 shares of the company’s stock valued at $395,000 after acquiring an additional 1,100 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in shares of Neurocrine Biosciences by 7.5% in the fourth quarter. Daiwa Securities Group Inc. now owns 6,481 shares of the company’s stock valued at $854,000 after acquiring an additional 451 shares in the last quarter. HealthInvest Partners AB purchased a new position in Neurocrine Biosciences during the fourth quarter worth about $1,662,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Neurocrine Biosciences by 128.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 44,939 shares of the company’s stock worth $5,921,000 after buying an additional 25,245 shares during the period. Finally, Mackenzie Financial Corp lifted its position in Neurocrine Biosciences by 1.3% during the fourth quarter. Mackenzie Financial Corp now owns 96,855 shares of the company’s stock worth $12,762,000 after buying an additional 1,224 shares during the period. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Neurocrine Biosciences

In related news, Director Richard F. Pops sold 15,000 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $132.47, for a total transaction of $1,987,050.00. Following the completion of the sale, the director now owns 29,512 shares in the company, valued at approximately $3,909,454.64. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, insider Darin Lippoldt sold 10,000 shares of the stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $139.86, for a total value of $1,398,600.00. Following the completion of the transaction, the insider now directly owns 35,882 shares of the company’s stock, valued at approximately $5,018,456.52. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Richard F. Pops sold 15,000 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $132.47, for a total value of $1,987,050.00. Following the completion of the transaction, the director now directly owns 29,512 shares of the company’s stock, valued at $3,909,454.64. The disclosure for this sale can be found here. In the last quarter, insiders sold 196,994 shares of company stock worth $27,205,009. 4.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Wells Fargo & Company increased their target price on Neurocrine Biosciences from $127.00 to $140.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 8th. Wedbush restated an “outperform” rating and set a $147.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, April 10th. The Goldman Sachs Group boosted their price objective on Neurocrine Biosciences from $134.00 to $153.00 and gave the company a “buy” rating in a research report on Thursday, January 25th. Finally, JPMorgan Chase & Co. boosted their price objective on Neurocrine Biosciences from $148.00 to $158.00 and gave the company an “overweight” rating in a research report on Wednesday, March 20th. Six equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $139.67.

Neurocrine Biosciences Trading Up 0.3 %

NASDAQ NBIX traded up $0.39 on Thursday, reaching $133.62. The stock had a trading volume of 51,313 shares, compared to its average volume of 840,020. The company has a market capitalization of $13.30 billion, a price-to-earnings ratio of 55.21 and a beta of 0.25. The business has a 50 day moving average price of $136.19 and a 200 day moving average price of $126.81. Neurocrine Biosciences, Inc. has a 1 year low of $89.04 and a 1 year high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.31. The company had revenue of $515.20 million during the quarter, compared to the consensus estimate of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The firm’s revenue was up 25.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.88 EPS. On average, analysts anticipate that Neurocrine Biosciences, Inc. will post 4.84 earnings per share for the current fiscal year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.